


Ozagrel

Cat. No.:	HY-B0428		
CAS No.:	82571-53-7		
Molecular Formula:	C ₁₃ H ₁₂ N ₂ O ₂		
Molecular Weight:	228.25		
Target:	Prostaglandin Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (219.06 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	4.3812 mL	21.9058 mL	43.8116 mL
	5 mM	0.8762 mL	4.3812 mL	8.7623 mL
	10 mM	0.4381 mL	2.1906 mL	4.3812 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Ozagrel (OKY-046) is an anti-asthmatic agent and a thromboxane A₂ (TXA₂) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM^[1].

IC₅₀ & Target

TXA₂

CUSTOMER VALIDATION

-
- Nat Commun. 2020 Apr 14;11(1):1792.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Max Seidy Saito, et al. Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization. J Enzyme Inhib Med Chem. 2016 Dec;31(6):1591-601.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA